Efficacy And Safety of Bismuth-Tetracycline-Rabeprazole Triple For First-Line Eradication of Helicobacter Pylori Infection

Most international treatment guidelines currently recommend a 14‐day bismuth quadrupletherapy as the first‐line treatment for Helicobacter pylori infection, especially inareas with high clarithromycin resistance. While this therapy boasts good eradicationrates, its administration is complex and has a high incidence of adverse reactions.However, tetracycline is one of the most effective anti‐Helicobacter pylori antibiotics,with a resistance rate of less than 3%. This study prospectively evaluates the efficacyand safety of a 14‐day triple therapy (high‐dose tetracycline combined with bismuth andPPI) versus a 14‐day bismuth quadruple therapy as first‐line eradication therapy. Thisnovel single‐antibiotic therapy has the potential to become a new standard of care forHelicobacter pylori eradication.